Hepatobiliary division in Kaohsiung Medical University Hospital (KMUH) was the most early medical institution to perform “ Individualized Therapeutic Strategies “. We use diverse way to keep patients using medication, and the result is promising. After shortening the duration of treatment, the success rate of treatment increased, and the side effects decreased. The experience was used as guideline forTaiwan Association for the Study of the Liver (TASL) and The Gastroenterological Society of Taiwan. The idea and innovation also became the mainstream of treatment in hepatitis C. The “ Individualized Therapeutic Strategies “ was reward for National Quality Certification in 2017 and bronze medal of Symbol of National Quality in 2008.
The specific approach to “personalized treatment of chronic hepatitis C” is to determine the length of the treatment course based on factors such as the virus genotype of the patient, the rapid viral response after treatment with the early viral response, and the concentration of the virus before the treatment. By promoting the "C hepatitis treatment with IL-28B translation medical tools" to achieve the clinical application of interferon therapy using IL-28B and viral factor treatment courses to increase the success rate of treatment and reduce the unnecessary waste of medical resources.
In the current era of small-molecule antiviral drugs, focusing on the differences between East-West treatment and cost-effectiveness considerations, we use the IL28B translational medical tools, based on the personalized medicine, to provide better quality of care for the patient who getting hepatitis C.
In addition, we actively carry out the research including international-level epidemiology of liver diseases, basic and clinical medicine, and health education, etc. Cooperating with government policies to promote the prevention and treatment of liver diseases for provide all-round and high-quality liver care. Actively enter the community and build a close interaction to enhance the high-quality liver diseases prevention and treatment .
Chronic hepatitis C virus infection is an important cause of cirrhosis and hepatocellular carcinoma in humans. About 1 to 5% of adult populations is infected with hepatitis C virus in our country, and the prevalence of hepatitis C in some regions in southern Taiwan is as high as 20% or more. More than 20% of hepatitis C patients have liver cirrhosis within 20 years, and 2-7% of the above patients will develop hepatocellular carcinoma after liver cirrhosis. Therefore, the prevention and treatment of hepatitis C is extremely important for health care and clinical care. It is hoped that the individual therapy organized by National Chung-Shan Institute of Science and Technology Institute can increase the rate of sustained virological response, achieve better therapeutic effects, reduce the cost of treatment, and improve patient medication safety through the implementation of this plan.